General
Preferred name
IMATINIB
Synonyms
Gleevec, Imatinib mesylate, STI-571 ()
Gleevec ()
Gleevec,STI-571 ()
IMATINIB MESYLATE ()
Glivec ()
CGP-57148B ()
STI-571 ()
ST-1571 Mesylate ()
STI571 ()
CGP057148B ()
ST-1571 ()
IMATINIB ()
Imatinib (Mesylate) ()
STI571 (Mesylate) ()
CGP-57148B (Mesylate) ()
Gleevec, Glivec, CGP-57148B,STI571 ()
STI571,Gleevec, Glivec, CGP057148B ()
Imatinib (STI571) Mesylate ()
Imatinib (STI571) ()
Imatinib mesylateGleevecGlivecImatinibSTI571CGP 571484-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]benzamide ()
GLAMOX ()
NSC-743414 ()
NSC-759854 ()
Imatinib-d3 ()
Imatinib methanesulfonate ()
QTI571 ()
Imatinib actavis ()
Imatinib medac ()
Imatinib mesilate ()
Imatinib accord ()
QTI-571 ()
Imatinib teva b.v. ()
NSC-716051 ()
Imatinib methane sulfonate ()
Imatinib (as mesilate) ()
STI 571 ()
Imatinib teva ()
Imatinib koanaa ()
P&D ID
PD001319
CAS
152459-95-5
220127-57-1
1080014-82-9
1134803-18-1
Tags
available
probe
drug
Approved by
FDA
EMA
First approval
2001
Drug indication
Intestinal cancer
acute lymphoblastic leukemia
Acute lymphoblastic leukaemia
chronic myelogenous leukemia
Middle East Respiratory Syndrome (MERS)
Lung cancer
Severe acute respiratory syndrome (SARS)
Chronic myelogenous leukaemia
Systemic mastocytosis
Drug Status
approved
Max Phase
4.0
Probe info
Probe type
calculated probe
experimental probe
Probe sources
Chemical Probes.org
Tool Compound Set
Probe targets
[[ compound.targets[t].gene_name ]]
Probe control
Probe control not defined
Orthogonal probes
57
No orthogonal probes found
Similar probes
10
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS
Imatinib is an antineoplastic agent and a 2-phenylaminopyrimidine derivative that is used to treat chronic myelogenous leukemia. It works as a specific inhibitor of a number of tyrosine kinase enzymes. Chronic myelogenous leukemia is associated with the Philadelphia chromosome promoting the generation of BCR-ABL mutation, which results from the combination of two genes, known as BCR and ABL. BCR-ABL generates a fusion protein that acts as a constitutively active tyrosine kinase and imatinib works to inhibit this constitutive enzymatic activity.
TOXICITY
The most frequently reported adverse reactions (>30%) were edema, nausea,; vomiting, muscle cramps, musculoskeletal pain, diarrhea, rash, fatigue and; abdominal pain.
COMMENT
Imatinib is a non-selective kinase inhibitor originally developed as a tyrosine kinase inhibitor, as shown in several papers (Nature Biotechnology 23, 329 - 336 (2005) ; Nature Biotechnology 26, 127 - 132 (2008) ). Imatinib is a potent inhibitior of ABL (Kis in the 10s of nM), DDR1 (Ki=0.8 nM), DDR2 (Ki=15 nM), KIT (Ki=14 nM), LCK (K=40 nM), PDGFRB (Ki=14 nM), PDGFRA (Ki=30 nM) and has affinity for many other kinases (see http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=screens...). Imatinib also has high affinity for the human quinone reductase 2 (NQO2) (Ki=80 nM; BMC Struct Biol. 2009; 9: 7). Jun 12 2016 - 1:44pm; This compound has inadequate selectivity to be considered a probe. Jun 12 2016 - 1:44pm
DESCRIPTION
Imatinib is a Type-2 kinase inhibitor. Its main inhibitory activity is against ABL kinase, but it has significant action at secondary targets including platelet-derived growth factor receptor (PDGFR) and stem cell growth factor receptor (KIT).
Coronavirus: imatinib is reported to block Spike protein-induced SARS-CoV and MERS-CoV fusion in vitro , potentially by blocking Abl2 at the endosomal membrane and disrupting the actin dynamics that are required for virus-host fusion . It will be informative to determine if this holds true for SARS-CoV-2, and whether re-purposing of imatinib and/or newer Abl kinase inhibitors (, , , ) could be a viable strategy against COVID-19. This approach would likely to be most effective during the early stage of infection.
Imatinib also demonstrates antimycobacterial activity, increasing the host macrophage response to infection with Mycobacterium tuberculosis, with potential for this drug to be repurposed as an adjuvant therapy against drug-resistant tuberculosis . (GtoPdb)
Coronavirus: imatinib is reported to block Spike protein-induced SARS-CoV and MERS-CoV fusion in vitro , potentially by blocking Abl2 at the endosomal membrane and disrupting the actin dynamics that are required for virus-host fusion . It will be informative to determine if this holds true for SARS-CoV-2, and whether re-purposing of imatinib and/or newer Abl kinase inhibitors (, , , ) could be a viable strategy against COVID-19. This approach would likely to be most effective during the early stage of infection.
Imatinib also demonstrates antimycobacterial activity, increasing the host macrophage response to infection with Mycobacterium tuberculosis, with potential for this drug to be repurposed as an adjuvant therapy against drug-resistant tuberculosis . (GtoPdb)
DESCRIPTION
Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively[1][2][3][4]. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV[5].
PRICE
29
PRICE
29
DESCRIPTION
Imatinib Mesylate (STI571 Mesylate) is a tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC50=100 nM) tyrosine kinases.
DESCRIPTION
Imatinib Mesylate (STI-571) is a tyrosine kinase receptor inhibitor with antineoplastic activity (IC50s: 0.6 ??M, 0.1 ??M and 0.1 ??M for v-Abl, c-Kit and PDGFR, respectively).
MOA
Inhibitor
(Chemical Probes.org)
DESCRIPTION
inhibitor of BCR-ABL1 and c-KIT
(Informer Set)
DESCRIPTION
For the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML), Ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST).
(PKIDB)
DESCRIPTION
Imatinib is an oral chemotherapy medication used to treat cancer. It is a tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity.
(Enamine Bioactive Compounds)
DESCRIPTION
Imatinib (STI571) is a multi-targeted receptor tyrosine kinase inhibitor that selectively inhibits the kinase activities of BCR/ABL, v-Abl, PDGFR, and c-kit with oral activity. Imatinib has antitumor activity for the treatment of chronic granulocytic leukemia.
(TargetMol Bioactive Compound Library)
DESCRIPTION
MSK/RSK family kinase inhibitor
(Tocris Bioactive Compound Library)
DESCRIPTION
Imatinib Mesylate (STI-571) is a tyrosine kinase receptor inhibitor with antineoplastic activity (IC50s: 0.6 μM, 0.1 μM and 0.1 μM for v-Abl, c-Kit and PDGFR, respectively).
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
198
Organisms
5
Compound Sets
47
Axon Medchem Screening Library
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
Chemical Probes.org
Clinical kinase drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP Approved Drugs
DrugMatrix
Enamine Bioactive Compounds
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
Informer Set
Ki Database
Kinase Inhibitors (best-in-class)
LSP-MoA library (Laboratory of Systems Pharmacology)
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
NCATS Inxight Approved Drugs
NIH Approved Oncology Drugs
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Pandemic Response Box
PKIDB
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
The Spectrum Collection
Tocris Bioactive Compound Library
Tool Compound Set
Welcome Trust Cancer Drugs
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
85
Molecular Weight
493.26
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
2
Rotatable Bonds
7
Ring Count
5
Aromatic Ring Count
4
cLogP
4.59
TPSA
86.28
Fraction CSP3
0.24
Chiral centers
0.0
Largest ring
6.0
QED
0.39
Structural alerts
2
aggregator (Aggregator Advisor)
Aggregators
aggregator (ZINC)
Aggregators
Related compounds
Custom attributes
(extracted from source data)
Target
ABL1
BCR
KIT
ABL, KIT, PDGFR
Platelet-derived growth factor receptor beta
Stem cell growth factor receptor
Tyrosine-protein kinase ABL
ABL1, PDGFRA, PDGFRB, KIT
ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET
Bcr-Abl inhibitor
BCR-ABL, PDGFR, KIT
SARS-CoV
Autophagy,Bcr-Abl,c-Kit,PDGFR
RET
NTRK1
CSF1R
PDGFRA
DDR1
PDGFRB
ABL1, KIT
v-Abl
Compound status
FDA
Pathway
ABL signaling
Angiogenesis
Autophagy
Cytoskeletal Signaling
Tyrosine Kinase/Adaptors
Microbiology/virology
Anti-infection
Protein Tyrosine Kinase/RTK
Known off targets
PDGFR, v-Abl
Kinase group
TK
MOA
receptor protein-tyrosine kinase inhibitor
Bcr-Abl
c-Kit
PDGFR
Inhibitor
Abl Kinase Inhibitors
Bcr-Abl Kinase Inhibitors
Inhibitors of Signal Transduction Pathways
Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor
Targets
ABL1,KIT,PDGFRA,PDGFRB
Primary Target
Abl Kinase
Member status
virtual
Indication
chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)
Disease Area
hematologic malignancy, oncology
Target class
Protein kinase
Kinase, Kinase
Orthogonal probe
GNF-5
Therapeutic Class
Antiviral Agents
Anticancer Agents
Target subclass
TK, TK
Source data
